RedHill details Rebyota, Clenpiq deal terms and market data for Ferring GI drugs

RedHill Biopharma Ltd. provided additional detail on its acquisition of commercialization rights to Rebyota and Clenpiq from Ferring Pharmaceuticals, following its September 1, 2026 announcement.

On payment structure, the transaction included an upfront payment of $12 million to Ferring, tiered royalties of 5% to 20% on net sales and potential capped sales milestones and certain other contingent payments, in each case subject to specified future events.¹ The agreement also provides for the purchase of existing Rebyota inventory with deferred payment terms and minimum annual purchase commitments for Rebyota during 2027 through 2029, and Ferring will continue to manufacture and supply the products during the term, while RedHill's subsidiary holds the exclusive right and responsibility to commercialize them in the applicable territories.¹ The agreement has an initial term of thirteen years, with automatic renewals for successive two-year periods unless either party elects not to renew.¹

On the underlying market, RedHill's release cited industry data showing colonoscopy is the cornerstone of GI practice, with more than 15 million colonoscopies performed in the U.S. annually¹, and noted Rebyota's one-time administration, which requires no fasting, bowel prep or extended treatment timeframe, has demonstrated more than a 70% success rate at preventing rCDI¹ in the cited study.

The release also reiterated financial figures for the two products: Rebyota generated approximately $16.9 million in U.S. net sales in 2025¹, while Clenpiq delivered $20.6 million in net sales in 2025, with minimal promotion.¹